Lincoln Pharmaceuticals (NSE:LINCOLN) FFO


NSE:LINCOLN Lincoln Pharmaceuticals Ltd NSE:LINCOLN
84 GF Score
Price ₹619.65
GF Value ₹706.85
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Lincoln Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

NSE:LINCOLN
84GF Score
Lincoln Pharmaceuticals Ltd NSE:LINCOLN
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lincoln Pharmaceuticals (NSE:LINCOLN) Overvalued in 2026?

Based on GuruFocus' analysis, Lincoln Pharmaceuticals stock appears to be undervalued. The current stock price of ₹619.65 is trading 12.3% below its estimated GF Value™ of ₹706.85. GuruFocus considers Lincoln Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for NSE:LINCOLN:

  • FFO:
  • GF Value™: ₹706.85 vs. price of ₹619.65 (12.3% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the NSE:LINCOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lincoln Pharmaceuticals Business Description

Other Exchanges 531633:India
Address Science City Road, Lincoln House, Behind Satyam Complex, Sola, Ahmedabad, GJ, IND, 380060
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.
84GF Score

Get the complete analysis for NSE:LINCOLN

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹619.65
Price
₹706.85
GF Value